Lanreotide Acetate
NDC Package 76282-710-67

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Lanreotide Acetate is a . Marketed by Exelan Pharmaceuticals, Inc., this product is identified by NDC 76282-710 and is authorized under FDA application NDA215395.

Identification & Billing

NDC Package Code
76282-710-67
Package Description
1 SYRINGE in 1 CARTON / .3 mL in 1 SYRINGE
Product Code
76282-710
11-Digit Billing Format
76282071067

Clinical Specifications

Proprietary Name
Lanreotide Acetate
Dosage Form
-

Regulatory & Marketing

Labeler Name
Exelan Pharmaceuticals, Inc.
FDA Application #
NDA215395
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-01-2022
End Marketing Date
08-18-2023
Listing Expiration
08-18-2023
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 76282-710-67 identifies a specific commercial package of 1 syringe in 1 carton / .3 ml in 1 syringe of Lanreotide Acetate, labeled by Exelan Pharmaceuticals, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Exelan Pharmaceuticals, Inc. on June 01, 2022. The current certification is valid through August 18, 2023.

How is this Exelan Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 76282071067. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
76282-710-67
11-Digit CMS (5-4-2)
76282-0710-67

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.